The perspectives of adjunctive drugs usage in the treatment of glucose metabolism disturbances in adolescent patients.
Tightening of the diabetes control criteria in the last few years induces searches for adjunctive drugs to reinforce the basic treatment typical for the specific type of the disease. These agents are meant to stimulate insulin secretion, increase insulin sensitivity or inhibit the antagonists of the hormone. Up till now that kind of studies included adults, mainly with type 2 diabetes. Nowadays, however, the increasing number of research focuses on type 1 diabetic patients. The attempts to introduce this type of treatment in adolescent patients encounter many limitations, mostly of formal nature due to drug registration requirements. Nevertheless, more and more studies point at the efficacy of these agents and the possibility of their usage also in adolescents with different types of diabetes.
Otto-Buczkowska
Ewa
E
Górnoślaskie Centrum Zdrowia Dziecka w Katowicach. em.buczkowski@pro.onet.pl
Machnica
Łukasz
Ł
D000273:Adipose Tissue / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000682:Amyloid / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D054439:Ghrelin / Q000378:metabolism; D005934:Glucagon / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000145:classification / Q000627:therapeutic use*; D058228:Islet Amyloid Polypeptide; D008297:Male; D043882:Receptors, Cannabinoid / Q000378:metabolism
D000682:Amyloid; D054439:Ghrelin; D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; D043882:Receptors, Cannabinoid; D052216:Glucagon-Like Peptide 1; D005934:Glucagon